Project Grant R41HL182448
Award Date 9/1/26
Completion Date 3/31/27
Dollars Obligated $346K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ithaca, NY 14853, USA
Similar Awards
- This Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $274,811 to Anova Biomedical, Inc. to develop 3D printed personalized vascular grafts using novel elastomeric resins. The key objectives are to: 1) develop and characterize the novel 3D printing resin for producing personalized, elastic, and bioresorbable vascular grafts; 2) demonstrate the ability to 3D print vascular prosthetics using patient CT...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Angiograft LLC $314,081 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop acellular tissue-engineered vascular grafts (ATEVs) for dialysis access applications. Angiograft will establish the feasibility of engineered collagen-based ATEV grafts constructed from small intestinal submucosa functionalized with cross-linked heparin by testing them...
- The National Heart, Lung, and Blood Institute awarded The Research Foundation For The State University of New York $740,447 on August 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to engineer self-healing, tissue-engineered vascular grafts for use as arteriovenous shunts in hemodialysis patients. The award funds development of self-healing tissue-engineered vessels (SH-TEVs) designed to withstand repeated needle cannulation while maintaining mechanical strength and...
- This Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program provides $304,906 to Seabird Lifesciences LLC for the development of a novel bioprinting approach to create vascular grafts. The project aims to produce a next-generation vascular graft that improves outcomes for patients undergoing vascular surgeries by enhancing tissue integration, improving long-term performance, and reducing the need for repeat...
- The National Heart, Lung, and Blood Institute awarded Yale University $688,062 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop tissue-engineered arteriovenous grafts from human induced pluripotent stem cells for hemodialysis vascular access in end-stage renal disease patients. The project addresses the clinical failure of current synthetic arteriovenous grafts, which suffer thrombosis, neointimal hyperplasia, infection, and aneurysm due to...
- The National Heart, Lung, and Blood Institute awarded $775,114 to the Research Institute At Nationwide Children's Hospital on June 12, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct preclinical evaluation of a cell-free tissue-engineered vascular graft designed for congenital heart surgery. The research addresses complications arising from prosthetic biomaterials currently used in surgical repair of complex congenital cardiac anomalies, including thromboembolic...
- The National Heart Lung and Blood Institute awarded Venostent, Inc. $1,016,974 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support pilot-scale synthesis and commercialization of SelfWrap, a bioabsorbable perivascular wrap designed to improve outcomes in arteriovenous fistula creation and other vascular surgeries. SelfWrap addresses the high failure rate of arteriovenous fistulas (AVFs) created for hemodialysis access. Veins used in AVF surgery are...
- The National Heart, Lung, and Blood Institute awarded Northwestern University $812,196 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 15, 2026, to conduct research on targeted NAD+ replenishment as pre- and post-bypass therapy against vein graft failure. The research addresses the clinical problem that up to 20 percent of vein grafts fail within the first year following bypass surgery, and nearly half are occluded by 10 years. The award funds investigation of...
- The National Heart, Lung, and Blood Institute awarded MDC Studio, Inc. $309,813 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop an automated vascular access device that enables less-experienced providers to safely and reliably perform central venous and arterial cannulation. The R61 phase focuses on automating the core steps of successful cannulation. MDC Studio will design, construct, and test sensors and automation to detect blood vessel...
- The National Heart, Lung, and Blood Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded $697,198 to the University of Texas at Austin on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate sex-biased integrin-mediated endothelialization processes for precision vascular graft design. The recipient is conducting research to identify how biological sex affects endothelial cell behavior in response...